Skip Navigation


Hum. Reprod. Advance Access originally published online on March 10, 2005
Human Reproduction 2005 20(5):1390-1397; doi:10.1093/humrep/deh721
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
20/5/1390    most recent
deh721v3
deh721v2
deh721v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tartakover Matalon, S.
Right arrow Articles by Lishner, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tartakover Matalon, S.
Right arrow Articles by Lishner, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions{at}oupjournals.org

The effect of 6-mercaptopurine on early human placental explants

S. Tartakover Matalon1,4, A. Ornoy3, A. Fishman2, L. Drucker1 and M. Lishner1

1 Oncogenetic laboratory, Department of Medicine ‘A’ and 2 Department of Obstetrics & Gynecology, Sapir Medical Center, Kfar-Saba 44281 Tel-Aviv University, Tel-Aviv, Israel and 3 Laboratory of Teratology, Department of Anatomy and Cell Biology, Hebrew University Hadassah Medical School, Jerusalem, Israel

4 To whom correspondence should be addressed at: Oncogenetic Laboratory, Sapir Medical Center, 45 Tshernehovski street, Kfar-Saba, 44281, Tel-Aviv University, Tel Aviv, Israel. Email: matalon.shelly{at}clalit.org.il

BACKGROUND: 6-mercaptopurine (6-MP) is an antineoplastic and immunosuppressive drug. Recently, more women have received this drug during pregnancy. Animal studies have shown that 6-MP has deleterious effects on the fetus, while human data include prematurity, intrauterine growth restriction, low birth weight and malformations that occur especially when the drug is administered in the first trimester of pregnancy. OBJECTIVES: To study the effects of 6-MP on cellular functions of human trophoblast explants. METHODS: Human placental explants (5.5–9 weeks gestational age), that were grown on matrigel, were exposed to medium containing 6-MP for 5 days. Medium alone served as control. Extravillous trophoblast (EVT) cell migration assessment was performed by visual observation. Analysis of proliferating events of the trophoblast cells was asessed by immunohistochemical examination. Apoptosis was analyzed by Tunnel procedure and by anti-caspase 3 staining and hormone level by enzyme-linked immunosorbent assay. RESULTS: 6-MP inhibited migration of EVT cells from the villi to the matrigel with a lower proliferation rate and increased apoptosis of cytotrophoblast cells compared to controls. However, no significant effect of 6-MP on hormone levels was observed. CONCLUSIONS: 6-MP inhibited migration and proliferation of trophoblast cells in first-trimester human placental explant culture.

Key words: 6-mercaptopurine/migration/placenta/pregnancy/proliferation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
D. Pereg, G. Koren, and M. Lishner
The treatment of Hodgkin's and non-Hodgkin's lymphoma in pregnancy
Haematologica, September 1, 2007; 92(9): 1230 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Tartakover-Matalon, N. Cherepnin, M. Kuchuk, L. Drucker, I. Kenis, A. Fishman, M. Pomeranz, and M. Lishner
Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression
Hum. Reprod., April 1, 2007; 22(4): 1161 - 1167.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.